Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Clinical Efficacy and Safety of Oral Decitabine/Cedazuridine in 133 Patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-133855

Published: 2020

Journal Articles

Central Nervous System Lymphoma: Analysis of the Texas Cancer Registry

Cesar Gentille Sanchez, MD, Ethan Burns, MD, Ibrahim Muhsen, MD, Humaira Sarfraz, MD, Carlo Guerrero, MD, Jasleen K. Randhawa, MD, Shilpan S. Shah, MD, Joe Ensor, PhD, Sai Ravi Kiran Pingali, MD

Blood (2020) 136 (Supplement 1): 45–46.

https://doi.org/10.1182/blood-2020-142487

Published: 2020

Journal Articles

Primary and Secondary Central Nervous System Lymphoma: Outcomes from Houston Methodist Cancer Center

Cesar Gentille Sanchez, MD, Ethan Burns, MD, Ibrahim Muhsen, MD, Humaira Sarfraz, MD, Carlo Guerrero, MD, John T Rogers, MD, Matthew D Cykowski, MD, Joe Ensor, PhD, Kirk Heyne, MD, Jorge G. Darcourt, MD, Jasleen K. Randhawa, MD, Shilpan S. Shah, MD, Sai Ravi Kiran Pingali, MD

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-142560

Published: 2020

Journal Articles

Primary Cutaneous Anaplastic Large-Cell Lymphoma: A Surveillance, Epidemiology, and End Results Database Analysis from 2005-2016

Cesar Gentille Sanchez, MD, Joe Ensor, PhD, Akshjot Puri, MD, Jasleen K. Randhawa, MD, Shilpan S. Shah, MD, Sai Ravi Kiran Pingali, MD

Blood (2019) 134 (Supplement_1): 4022.

https://doi.org/10.1182/blood-2019-131991

Published: 2019

Journal Articles

An Integer Weighted Genomic Mutation Score (GMS) Using Next Generation Sequencing Is Predictive of Prognosis in Intermediate Risk AML Patients

Akash Mukherjee, MD, Xinyu Nan, MD, Joe Ensor, PhD, Jasleen K. Randhawa, MD, Sai Ravi Kiran Pingali, MD, Arthur William Zieske, MD, Randall J Olsen, MD, Betty Chung, DO,MPH,MA, Swami P. Iyer, MD

Blood (2017) 130 (Supplement 1): 3940.

https://doi.org/10.1182/blood.V130.Suppl_1.3940.3940

Published: 2017

Journal Articles

Rothman Index As a Real-Time Predictor of Intensive Care Unit Admissions and Mortality in Acute Myeloid Leukemia Patients Undergoing Induction Chemotherapy

Deepa Gotur, MD MBBS, Sai Ravi Kiran Pingali, MD, Lawrence Rice, MDBA, Ibrahim F. Ibrahim, MD, Janice L Zimmerman, MD FCCP, FCCM, Stephen Wong, PhD, Christopher Jude Cortes, MD, Mamta Puppala, MSc, Zheng Yin, PhD, Jasleen K. Randhawa, MD, Swami P. Iyer, MD

Blood (2017) 130 (Supplement 1): 3444.

https://doi.org/10.1182/blood.V130.Suppl_1.3444.3444

Published: 2017

Journal Articles

Updated Phase II Study of Targeted Subcutaneous (SC) Bortezomib for Patients with Low- or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndrome (MDS) with Evidence of NF-κb Activation

May Daher, MD, Juliana Elisa Hidalgo Lopez, MD, Jasleen K. Randhawa, MD, Kausar Jabeen Jabbar, MD, Naveen Pemmaraju, MD, Gautam Borthakur, MD, Tapan M. Kadia, MD, Marina Konopleva, MD PhD, Hagop M. Kantarjian, MD, Jorge E. Cortes, MD, Katherine P. Hearn, BSN, RN, Steven R. Reyes, MS, Carlos E. Bueso-Ramos, MD PhD, Guillermo Garcia-Manero, MD

Blood (2016) 128 (22): 3191.

https://doi.org/10.1182/blood.V128.22.3191.3191

Published: 2016

Journal Articles

Phase II Study of Targeted Subcutaneous (SC) Bortezomib for Patients with Low- or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndrome (MDS) with Evidence of NF-κB Activation

Jasleen K. Randhawa, MD, Kausar Jabeen Jabbar, Tapan Kadia, MD, Gautam Borthakur, MD, Naveen Pemmaraju, MD, Naval Daver, MD, Hagop M. Kantarjian, MD, Jorge E. Cortes, MD, Katherine Hearn, RN, Carlos E. Bueso-Ramos, MD PhD, Guillermo Garcia-Manero, MD

Blood (2014) 124 (21): 1930.

https://doi.org/10.1182/blood.V124.21.1930.1930

Published: 2014

Journal Articles

Results of a Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients (Pts) with Activating FLT3 Mutations

Jasleen K. Randhawa, MD, Hagop M. Kantarjian, MD, Gautam Borthakur, MD, Philip Alastair Thompson, MBBS,FRCPA,FRACP, Maria Konopleva, MD PhD, Naval Daver, MD, Naveen Pemmaraju, MD, Elias Jabbour, MD, Tapan M. Kadia, MD, Zeev Estrov, MD, Abhijit Ramachandran, PhD, Jamil Paradela, Michael Andreef, MD PhD, Mark Levis, MD PhD, Farhad Ravandi, MD, Jorge E. Cortes, MD

Blood (2014) 124 (21): 389.

https://doi.org/10.1182/blood.V124.21.389.389

Published: 2014

Journal Articles

Poor Response To Imatinib In Patients With Secondary Chronic Myelogenous Leukemia

Jonathan Thompson, MD,, Kendra L. Sweet, MD, Ling Zhang, MD, Jasleen K Randhawa, MD, Christopher R. Chitambar, MD, Jessica K Altman, MD, Javier Pinilla, MD, PhD, Ehab Atallah, MD

Blood (2013) 122 (21): 5170.

https://doi.org/10.1182/blood.V122.21.5170.5170

Published: 2013

Journal Articles

Bortezomib Based Therapy for Newly Diagnosed Patients with Advanced Multisystem Light Chain Amyloidosis (AL)

Leena Varkey Maramattom, MD, Mazie Froedtert Willms & Sue Froedtert Cancer Fellow, Veerpal Singh, MD, Robert Frank Cornell, MD, Jasleen K Randhawa, MD, Mathew Thomas, Ayman A Saad, MD, Jeanne Palmer, MD, Parameswaran Hari, MBBS, MD, MRCP

Blood (2011) 118 (21): 1880.

https://doi.org/10.1182/blood.V118.21.1880.1880

Published: 2011

Journal Articles

Hypomethylating Agent Therapy for Acute Myelogenous Leukemia (AML) Can Induce Sustained Responses with Low Induction Mortality.

Jasleen K Randhawa, MD, Christopher Bredeson, MD, Timothy S. Fenske, MD, Ayman Saad, MD, Jeanne Palmer, MD, Parameswaran N Hari, MD, Horatiu Olteanu, Ehab Atallah, MD

Blood (2009) 114 (22): 4157.

https://doi.org/10.1182/blood.V114.22.4157.4157

Published: 2009

Journal Articles

Response to Bortezomib Based Induction Therapy in Newly Diagnosed Light Chain (AL) Amyloidosis.

Veerpal Singh, MD, Ayman Saad, MD, Jeanne Palmer, MD, Jasleen K Randhawa, MD, Parameswaran N. Hari, MD, MS

Blood (2009) 114 (22): 1867.

https://doi.org/10.1182/blood.V114.22.1867.1867

Published: 2009

NARROW

Clinical Efficacy and Safety of Oral Decitabine/Cedazuridine in 133 Patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)

Central Nervous System Lymphoma: Analysis of the Texas Cancer Registry

Primary and Secondary Central Nervous System Lymphoma: Outcomes from Houston Methodist Cancer Center

Primary Cutaneous Anaplastic Large-Cell Lymphoma: A Surveillance, Epidemiology, and End Results Database Analysis from 2005-2016

An Integer Weighted Genomic Mutation Score (GMS) Using Next Generation Sequencing Is Predictive of Prognosis in Intermediate Risk AML Patients

Rothman Index As a Real-Time Predictor of Intensive Care Unit Admissions and Mortality in Acute Myeloid Leukemia Patients Undergoing Induction Chemotherapy

Updated Phase II Study of Targeted Subcutaneous (SC) Bortezomib for Patients with Low- or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndrome (MDS) with Evidence of NF-κb Activation

Phase II Study of Targeted Subcutaneous (SC) Bortezomib for Patients with Low- or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndrome (MDS) with Evidence of NF-κB Activation

Results of a Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients (Pts) with Activating FLT3 Mutations

Poor Response To Imatinib In Patients With Secondary Chronic Myelogenous Leukemia

Bortezomib Based Therapy for Newly Diagnosed Patients with Advanced Multisystem Light Chain Amyloidosis (AL)

Hypomethylating Agent Therapy for Acute Myelogenous Leukemia (AML) Can Induce Sustained Responses with Low Induction Mortality.

Response to Bortezomib Based Induction Therapy in Newly Diagnosed Light Chain (AL) Amyloidosis.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only